The use of PTH in the treatment of osteoporosis;Uso do PTH no tratamento da osteoporose

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 54, Issue 2, 2010, Pages 213-219

  Borba, Victória Z Cochenski ^a   Mañas, Nádila Cecyn Pietszkowski ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Anabolic; Osteoporosis; PTH; Teriparatide

Indexed keywords

EID: 77952704223     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302010000200018     Document Type: Review

References (38)

1. Pleiner-Duxneuner J, Zwettler E, Paschalis E, Roshger P, Nell-Duxneuner V, Klaushofer K. Treatment of osteoporosis with parathyroid hormone and teriparatide. Calcif Tissue Int. 2009;84:159-70.
2. Girotra M, Rubin MR, Bilezikian JP. Anabolic skeletal therapy for osteoporosis. Arq Bras Endocrinol Metab. 2006;50:745-54.
3. Neuprez A, Reginster JY. Bone-forming agents in the management of osteoporosis. Best Pract Res Clin End Met. 2008;22:869-83.
4. Migliaccio S, Brama M, Malavolta N. Management of glucocorticoids-induced osteoporosis: role of teriparatide. Ther Clin Risk Manag. 2009;5:305-10.
5. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007;40:1434-46.
6. Neer RM, Arnaud CD, Zancheta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-41.
7. Marcus R, Wang O, Satterwhite J, Mitlak B. The skeleton response to teriparatide is largely independent of age, initial bone mass density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res. 2003;18(1):18-23.
8. Lindsay R, Miller P, Pohl G, Glass EV, Chen P, Krege JH. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int. 2009;20(6):943-8.
9. Graeff C, Chevalier Y, Chalebois M, Varga P, Pahr D, Nickelsen TN, et al. Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from EUROFORS study. J Bone Miner Res. 2009;24:1672-80.
10. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM. Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res. 2001;16(1):157-65.
11. Aspenberg P, Genat HK, Johansson T, Nino AJ, Krohn K, Garcia-Hernadez PA, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Min Res. 2009 Jul 13 [Epub ahead of print]
12. Bouxsein ML, Chen EV, Glass EV, Kallmess DF, Delmas PD, Mitlak BH. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials. J Bone Joint Surg Am. 2009;91(6):1329-38.
13. Watts NB, Miller PD, Kohlmeier LA, Sebba A, Chen P, Wong M, et al. Vertebral fracture risk is reduced in women who loss femoral neck BMD with teriparatide treatment. J Bone Miner Res. 2009;24(6):1125-31.
14. Lau AN, Ali SH, Sawka AM, Thabane L, Papaionnou A, Gafni A, et al. Improvement in health-quality of life in osteoporosis patients treated with teriparatide. BMC Musculoskelet Disord. 2008;7(9):151.
15. Recker RR, Marin F, Ish-Shalom S, Moricke R, Hawkins F, Kapetanos G, et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res. 2009;24(8):1354-7.
16. Rubin MR, Bilezikian JP. New anabolic therapies in osteoporosis. Endocrinol Metab Clin North Am. 2003;32:285-308.
17. Glover SJ, Eastell R, McCloskey EV, Rogers A, Garnero P, Lowery J, et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone. 2009;45(6):1053-8.
18. Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukolis GN, Efstathiadou Z, et al. Head-to-head comparison of risedronate versus teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomized trial. Int J Clin Pract. 2008;62(6):919-24.
19. Black DM, Greenspan SL, Ensrud KE, Palermo L, Mc Gowan JA, Lang TF, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349(13):1207-15.
20. Finkelstein JS, Haves A. Hunzelan JL, Wyland JJ, Lee H, Meer RM. The effects of parathyroid hormone and alendronate, or both in men with osteoporosis N Engl J Med. 2003;349(13):1216-26.
21. File E, Deal C. Clinical update on teriparatide. Curr Rheumat Rep. 2008;11:169-76.
22. Cosman F, Nieves J, Dempster D, Lindsay R. Cyclic vs daily teriparatide therapy in previously untreated postmenopasual women and in those on prior alendronate. ASBMR 31st Annual Meeting. A0 900 2528.
23. Keel C, Kraenzlin ME, Kraenzlin CA, Muller B, Meier C. Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. J Bone Min Metab. 2009 Jun 17 [Epub ahead of print]
24. Dobnig H, Stepan JJ, Burr DB, Li J, Michalská D, Sipos A, et al. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Min Metab. 2009 May 19 [Epub ahead of print]
25. Cosman F, Wermers RA, Macuk KF, Xie L, Glass EV, Krege JH. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antireabsortive agent. J Clin Endocrinol Metab. 2009;94(10):3772-80.
26. Leder BZ, Neer RM, Wyland JJ, Lee HW, Burnerr-Bowie SA, Finkelstein JS. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab. 2009;94(8):2915-21.
27. Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forteo (EUROFORS). J Bone Miner Res. 2009;24(4):726-36.
28. Anastasilakis AD, Polyzoz Sa, Avramidis A, Papatheodorou A, Terpos E. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide. Horm Metab Res. 2009;41(7):559-62.
29. Saag KG, Shane E, Boonen S. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357:2028-39.
30. Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int. 2009 Apr 7 [Epub ahead of print].
31. Miller PD. Safety of parathyroid hormone for treatment of osteoporosis. Curr Osteoporos Rep. 2008;6:12-6.
32. Harper K, Frege JH, Marcus R, Mitlak BH. Osteosarcoma and teriparatide? J Bone Miner Res. 2007;22:334.
33. Subbiah V, Madsen VS, Raymond AK, Benjamin RS, Ludwig JA. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporosis Int. 2009 Jul 14 [Epub ahead of print]
34. Trevisani VFM, Riera R, Imato AM, Saconato H, Atallah AN. Teriparatide in postmenopausal women with osteoporosis: systematic review. Sao Paulo Med J. 2008;126(5):279-84. Review.
35. Verhaar HJ, Lems WF. PTH-analog: comparable or different? Arch Gerontol Geriatr. 2009;49(2):130-2.
36. Cosman F, Lane NE, Bolognese MA, Zanchetta JR, Garcia-Hernadez PA, Sees K, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2010;95(1):151-8.
37. Lunkdvist J, Johnell O, Cooper C, Sykes D. Economic evaluation of parathyroid hormone in the treatment of osteoporosis in postmenopausal women. Osteoporos Int. 2006;17:201-11.
38. Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med. 2006;166(11):1209-17.